| 00:00:01 | IT HAS BEEN SIGNIFICANT. |
| 00:00:18 | WE CLEARLY AGREE FROM THE TALK TODAY THAT THERE IS A LOT MORE THAT NEEDS TO BE DONE. |
| 00:00:24 | I WELCOME THE FIRST SPEAKER AND WE WILL DO THIS IN A PANEL DIALOGUE SETTING. |
| 00:00:30 | OUR FIRST IS PRESIDENT AND CEO OF THE PHARMACEUTICAL RESEARCH AND -- LEADS OVER 600,000 OF THEM. |
| 00:00:42 | TO DEVELOP NEW MEDICINES TO HELP PEOPLE LIVE LONGER AND MORE HEALTHY LIVES. |
| 00:00:47 | I AM VERY DELIGHT EDED AND IT'S BEEN UNDER A YEAR, RAL F? |
| 00:00:57 | EXACTLY ONE YEAR. |
| 00:01:06 | THE GPHA REPRESENTS FINISHED PHARMACEUTICAL PRODUCTS. |
| 00:01:11 | MANUFACTURERS AND DISTRIBUTORS. |
| 00:01:13 | AND THE SUPPLIER OF OTHER GOODS AND SERVICES TO THE GENERIC PHARMACEUTICAL INDUSTRY. |
| 00:01:20 | PLEASE WELCOME JOHN AND RALPH. |
| 00:01:28 | >> SO -- >> SO THIS PODIUM WILL MAKE IT SLIGHTLY MORE CHALLENGING. |
| 00:01:33 | I WILL GO THIS WAY AND MAKE IT EASIER. |
| 00:01:36 | I WOULD ACTUALLY LIKE, I HAVE ASKED BOTH GENTLEMEN IF IT WAS POSSIBLE, THE FOCUS OF THIS CONVERSATION IS THE VIEW FROM AN INDUSTRY. |
| 00:01:45 | AND THE INDUSTRY'S ROLL AND FROM EACH REPRESENTATIVE POSITION, WHAT THE INDUSTRY SAYS ABOUT THE IMPORTANCE OF THE ISSUE AND THE ROLL THEY HAVE PLAYED IN IT SO FAR. |
| 00:01:57 | I WILL FIRST TURN TO JOHN. |
| 00:02:03 | >> LET ME FIRST TELL YOU TO RELAX. |
| 00:02:07 | DON'T BE NERVOUS. |
| 00:02:11 | I AM DELIGHTED TO BE HERE. |
| 00:02:14 | AS RALPH AND I WERE TALKING ABOUT THIS IN A LOT OF OTHER ISSUES, THERE IS A NATURAL INCLINATION TO SAY THAT THE GENERICS AND BRANDED PHARMACEUTICALS HAVE A LOT THAT DIVIDES THEM. |
| 00:02:33 | THIS IS A CRITICAL ISSUE. |
| 00:02:35 | THERE IS ABSOLUTELY NO DAYLIGHT BETWEEN THE BRANDED PATENTED MEDICINE COMPANIES. |
| 00:02:55 | >> I KNOW YOU HAVE SPENT MOST OF THE MORNING TALKING ABOUT COUNTERFEIT. |
| 00:03:05 | >> I WANT TO REMIND OURSELVES THAT OVER 99%, WELL OVER 99% OF ALL MEDICINES THAT ARE PRESCRIBED, THAT ARE MANUFACTURED, THAT ARE DISPENSED AND TAKEN BY PATIENTS ARE ABSOLUTELY SAFE. |
| 00:03:24 | THEY ARE SAFE, EFFECT TIFF AND GENUINE. |
| 00:03:28 | REGULATORY SYSTEMS. |
| 00:03:42 | . AND WE JUST HAVE TO REMIND EVERYBODY THAT. |
| 00:03:46 | WE DON'T WANT TO SCARE EVERYBODY. |
| 00:03:48 | THERE IS REASON TO BE CONCERNED. |
| 00:03:51 | IN ORDER TO MAINTAIN THAT INTEGRITY INTEGRITY. |
| 00:04:02 | . WE HAVE VERY, VERY STRICT QUALITY REQUIREMENTS. |
| 00:04:10 | IT IS PEOPLE WHO VIOLATE THOSE WHO AVOID THOSE STRICT REQUIREMENTS AND THE INSPECTIONS THAT GO WITH THEM. |
| 00:04:25 | I THINK THAT IF THERE IS SOMETHING THAT BOTHERS ME THE MOST AND WHAT I HAVE LEARNED ABOUT THIS IS I AM VERY CONFIDENT IN OUR ABILITY TO STAY AHEAD OF THE BAD GUYS EXCEPT WHEN THEY USE THE INTERNET. |
| 00:04:49 | THOSE OF YOU WHO PICKED UP YOUR SMART PHONES, PROBABLY RECEIVED AN E-MAIL FROM YOUR BANK SAYING PLEASE CLICK ON THIS SITE OR BY YOUR INTERNET PROVIDER THAT SAYS PLEASE CLICK ON THIS SITE AND PROVIDE ADDITIONAL INFORMATION. |
| 00:05:04 | IT COMES UP FAST AND DISAPPEARS. |
| 00:05:15 | WE DO HAVE A VERY GOOD PROGRAM. |
| 00:05:19 | TALKED ABOUT HERE EARLIER TODAY. |
| 00:05:21 | THAT VERIFIES THE SITES. |
| 00:05:24 | BUT I'M SURE SOMEBODY HAS FIGURED OUT HOW TO REMEMBERLY KATE THE VERIFICATION. |
| 00:05:37 | NATIONALLY, GLOBALLY, AROUND THE WORLD TO REDUCE SO REDUCE THE CHANCE THAT ANYBODY ANYWHERE. |
| 00:05:52 | >> FIRST I WANT TO THANK THE PARTNERSHIP FOR SAFE MEDICINE. |
| 00:05:59 | AND TELL YOU HOW HONORED I AM TO BE WITH YOU. |
| 00:06:05 | IT'S BEEN A WONDERFUL OPPORTUNITY TO WORK ON SOME OF THE MOST IMPORTANT ISSUES IN THE HEALTH OF AMERICANS. |
| 00:06:13 | JOHN AND I STARTED MY SECOND OR THIRD WEEK ON THE JOB BY HAVING LUNCH TOGETHER AND PLEDGING TO ONE ANOTHER THAT WE WOULD SEEK OUT OUR OPPORTUNITIES TO WORK TOGETHER. |
| 00:06:26 | YES THERE WOULD BE SOME FRIENDLY COMPETITION. |
| 00:06:39 | NOTHING IS MORE ESSENTIAL TO WHAT WE DO THAN MAKING OUR PRODUCT SAFE YOU ALL KNOW THERE IS NO DIFFERENCES WITH RESPECT TO SAFETY EFFECTIVENESS AND QUALITY BETWEEN GENERICS AND THE BRANDS. |
| 00:07:09 | EVERYTHING WE DO IS PUT BEFORE THE FDA. |
| 00:07:12 | AND THEY LOOK AT OUR HISTORY OF COMPLIANCE. |
| 00:07:15 | THEY LOOK AT SAMPLE ANAL CEASE. |
| 00:07:17 | THEY ARE INVESTIGATING. |
| 00:07:18 | THIS IS THE SAFEST DRUG SUPPLY IN THE WORLD. |
| 00:07:22 | BUT WE KNOW WITH RESPECT, ESPECIALLY ON THE INTERNET. |
| 00:07:26 | THERE ARE PROBLEMS. |
| 00:07:40 | THE GENERIC DRUG UZER ACTS. |
| 00:07:43 | WE ARE PAYING $300 MILLION A YEAR WITH RESPECT TO ABBREVIATED APPROVALS, EXPEDITED APPROVALS OF NEW DRUG APPLICATIONS. |
| 00:07:52 | THEY ARE NOT THAT WELL KNOWN. |
| 00:07:54 | I THINK YOU WERE SUPPORTIVE OF THIS. |
| 00:07:57 | WAS GETTING MONEY TO MAKE SURE THAT ALL AROUND THE WORLD, NOT JUST IN AMERICA THE FDA AND THEIR ALLIES INTERNATIONALLY WERE MAKING SURE THAT THE PRODUCT S PRODUCTS WE BOTH WORK TOGETHER TO MAKE SURE THE FDA HAS THE MONEY TO DO ITS JOB. |
| 00:08:29 | THE FDA COULD BE MISSING $319 MILLION. |
| 00:08:33 | SO WE'RE GOING TO TRY TO ADDRESS THAT ISSUE. |
| 00:08:35 | BUT MOST IMPORTANTLY IN MATERIALS OF THIS PAST YEAR THIS WAS NOT A SUCCESS. |
| 00:08:39 | BUT IT WAS A NEAR SUCCESS AND JOHN AND I ARE GOING TO WORK TOGETHER THIS YEAR AND NEXT YEAR. |
| 00:08:44 | AND THAT HAS TO DO WITH THE PHARMACEUTICAL TRACEABILITY ENHANCEMENT CODE. |
| 00:08:54 | THE DISTRIBUTION SECURITY ALLIANCE. |
| 00:08:56 | ONE OF THE BEST COLLAPSE RATIONS I THINK I HAVE SEEN IN MY 35 YEARS IN WASHINGTON. |
| 00:09:01 | THE BRANDS, THE GENERICS, THE SUPPLIERS, THE WHOLESALERS. |
| 00:09:07 | EVERYONE IN THE SUPPLY CHAIN WORKING WITH REPUBLICANS AND DEMOCRATS TO MAKE SURE THAT WAS A NATIONAL SYSTEM TO PROTECT THE SECURITY OF OUR DRUG SUPPLY. |
| 00:09:32 | THEY DID A MAGNIFICENT JOB. |
| 00:09:34 | WE WERE UP UNTIL MIDNIGHT ON THE 15th, 16th, 17th OF JUNE, THIS FAR AWAY FROM GETTING A LAW. |
| 00:09:43 | THAT FAR AWAY. |
| 00:09:46 | WE'RE GOING TO GET IT. |
| 00:09:47 | I THINK THAT WILL ADDRESS MANY SUPPLY CHAIN ISSUES. |
| 00:09:55 | THE INTERNET ONE IS A GREAT ONE TO SINGLE OUT HOW WE CAN LEARN MORE, WORK WITH YOU ALL, WORK WITH ALL THE APPROPRIATE AGENCIES DOMESTICALLY AND INTERNATIONALLY TO GET THE JOB DONE. |
| 00:10:12 | >> IT'S CLEARLY FOR BRAND ENGINEERS. |
| 00:10:15 | IT'S NOT A FINANCIAL DISCUSSION. |
| 00:10:19 | THERE IS CLEARLY THE HEALTH FACTOR. |
| 00:10:25 | FROM THE PERSPECTIVE AS A WHOLE, WHAT WORRIES ARE STL IN THE ACTUAL REGULATED SUPPLY OR IS IT ABOUT EVERYTHING OUTSIDE OF THAT? |
| 00:10:38 | >> IT IS VERY MUCH A BOTTOM LINE ISSUE. |
| 00:10:44 | BUT NOT IN THE WAY YOU ARE THINKING. |
| 00:10:49 | IT ZUZ NOT HAVE A COST IMPACT DIRECTLY. |
| 00:10:54 | THE RESOURCES ARE NECESSARY TO GO AND PURSUE IT. |
| 00:10:57 | BUT THE FUNDAMENTAL BUSINESS MODEL OF WHAT BIOPHARMACEUTICAL COMPANIES DO IS ABSOLUTELY BASED ON THE FACT THAT PATIENTS, CLINICIANS AND PHYSICIANS TRUST THAT THE MEDICINE SS IT MAY BE A COUNTERFEIT MEDICINE. |
| 00:11:29 | I THINK IT'S TO THE HEART OF THE MODEL. |
| 00:11:43 | WITHOUT A STRONG BELIEF THAT OUR MEDICINES DO WHAT THE FDA AND WE SAY THEY ARE DOING FROM A THERAPEUTIC STANDPOINT, THEN NONE OF OUR SYSTEM WOULD BE TRUSTED. |
| 00:12:02 | WE CAME CLOSE. |
| 00:12:03 | WE ARE TOLD THAT THERE MAY BE A VEHICLE TO GET THIS ACCOMPLISHED BEFORE THE END OF THE YEAR. |
| 00:12:08 | BEFORE THE END OF THE YEAR NOW OF COURSE IS IN THE LAME DUCK SESSION. |
| 00:12:24 | ONE OF THE GREAT THINGS ABOUT WORKING ON IT IN THIS KIND OF POLITICAL ENVIRONMENT IS THAT EVERYTHING THAT WAS SET OUT TO BE ACCOMPLISHED WAS ACCOMPLISHED IN A BIPARTISAN WAY. |
| 00:12:39 | WITH THE INDUSTRY AND FDA. |
| 00:12:50 | THAT WOULD BE GOOD FOR PATIENTS AND SCIENCE GOING FORWARD. |
| 00:12:58 | NOW THE SAFE DOSES ACT HAS BEEN PASSED BY THE SENATE. |
| 00:13:06 | THAT'S AWAITING THE PRESIDENT'S SIGNATURE. |
| 00:13:08 | ONE OF THE THINGS THAT IS NECESSARY IS THAT THIS HAS TO BE A GLOBAL ENTERPRISE. |
| 00:13:18 | THE LEADING PHARMACEUTICAL COMPANIES IN EUROPE AND IN JAPAN HAVE BANDED TOGETHER TO WORK WITH INTERPOOL TO MAKE SURE THAT INTERPOOL HAS ENOUGH RESOURCES TO GO AFTER THE BAD GUY SS I THINK WE WILL KICK THAT OFF HERE NEXT MONTH. |
| 00:13:49 | COUNTRY SPECIFIC ENFORCEMENT AGENCIES WITH THE GLOBAL PERSPECTIVE OF BER POOLS. |
| 00:13:54 | YES IT COSTS MONEY BUT IT IS MONEY WELL SPENT. |
| 00:13:57 | MORE IMPORTANTLY, IT GETS AT THE HARD OF THE TRUST THAT PATIENTS HAVE TO HAVE IN OUR MEDICINES. |
| 00:14:15 | >> I THINK AS YOU HAD MENTIONED EARLIER ON IT WAS NOT NECESSARILY THE CASE. |
| 00:14:20 | AND MORE IMPORTANTLY WHAT WE HAVE SEEN ON A GLOBAL SCALE PARTICULARLY IN THESE MARKETS THAT GENERICS ARE FACING A LOT OF THEM. |
| 00:14:33 | WHAT IS IT FROM YOUR PERSPECTIVE? |
| 00:14:36 | WHAT'S THE BELIEF? WHAT ARE YOU DEALING WITH? |
| 00:14:43 | >> I THINK THERE HAS BEEN TREMENDOUS PROGRESS WITH RESPECT TO EDUCATION AS I SAID BEFORE. |
| 00:14:55 | WHETHER IT'S WITHIN THE SUPPLY CHAIN OR THE UNITED STATES OR ANYWHERE IN THE WORLD, AS JOHN STATED AND I JUST WANT TO REWE WANT THE WORLD'S FULL FAITH AND CONFIDENCE IN THE INTEGRITY OF THE SUPPLY CHAIN. |
| 00:15:21 | WE HAVE MADE A LOT OF PROGRESS AND A LOT OF IT HAS TO DO WITH THE PARTNERSHIP FOR SAFE MEDICINE BUT WE NEED MUCH MORE EDUCATION. |
| 00:15:32 | WE HAVE TO SPEND MORE TIME DOING IT. |
| 00:15:37 | MORE RESOURCES. |
| 00:15:38 | WHAT I LIKE SO MUCH ABOUT WHAT EVERYONE IN THIS ROOM IS DOING. |
| 00:15:46 | I WAS TALKING ABOUT COLLABORATIONS AND PARTNERSHIPS. |
| 00:15:51 | JOHN PUT IT SO NICELY. |
| 00:15:53 | THESE ISSUES, I'M SO OPTIMISTIC. |
| 00:16:05 | THESE ISSUES ARE NATIONAL ECONOMIC ISSUES IN TERMS OF MAKING SURE THAT THE PHARMACEUTICAL THEEDS ARE GLOBAL SECURITY ISSUES AND I BELIEVE WE WILL MAINTAIN THE CONSENSUS. |
| 00:16:34 | I BELIEVE IN THE LAST YEAR WHETHER IT'S THE BRANCH OR THE NE JERICES. |
| 00:16:43 | TO ADDRESS DRUG SHORT AJS. |
| 00:16:45 | THESE ARE PRIVATE SECTOR, PUBLIC SECTOR PARTNERSHIPS AND WE HAVE TO KEEP ON FOCUSING ON THAT. |
| 00:16:51 | GOVERNMENT ALONE CAN'T DO IT. |
| 00:16:59 | WE HAVE GOT WORK TOGETHER AS AMERICANS TO MAKE SURE THAT THE PARER INSHIP AND ALL OF THESE ORGANIZATIONS THAT SO MANY OF YOU REPRESENT CONTINUE TO BE EFFECTIVE. |
| 00:17:08 | AND JOHN AND I I KNOW WITH MANY OTHERS ARE GOING TO DEVOTE RESOURCES AND MANY OTHERS. |
| 00:17:18 | >> YOU BOTH HAVE SAID BEFORE, BOTH WORKING ON TOGETHER WITH THE HOUSE AS WELL. |
| 00:17:26 | SO CLEARLY. |
| 00:17:27 | THAT IS WHY THIS DISCUSSION HAS BEEN SO IMPORTANT. |
| 00:17:31 | AND SO WHAT ARE SOME OF THE OTHER POLICY AREAS THAT YOU BOTH FEEL IS REALLY WHERE THE OPPORTUNITIES ARE. |
| 00:17:43 | INCREASES IN THE NUMBER OF LAW ENFORCEMENT THAT WE NEED. |
| 00:17:48 | I WILL LET YOU GO FIRST. |
| 00:17:52 | >> THERE ARE MANY AREAS WHERE JOHN AND I WILL BE WORKING TOT. |
| 00:17:58 | BUT THE EASIEST AREA IS THE SPACE THAT WE ARE TALKING ABOUT RIGHT NOW. |
| 00:18:05 | I MENTIONED BEFORE ABOUT RESOURCES FOR THE FDA AND MANY OF US BELOUNGE TO THE ALLIANCE FOR PROVIDING FUNDING FOR THE FDA. |
| 00:18:21 | THAT IS A TOP PRIORITY. |
| 00:18:23 | GETTING MORE APPROPRIATE RATIONS. |
| 00:18:26 | WE HAVE WORKED OUT THE USER FEES AND OF COURSE CONGRESS HAS HAD A REAL DEPARTURE FROM WHAT HAS HAPPENED. |
| 00:18:44 | TO THE FDA. |
| 00:18:45 | THAT'S GOING TO GET 900 NEW EMPLOYEES OVER A NUMBER OF YEARS TO THE FDA TO EXPEDITE, REVIEW AND MAKE SURE THEY THA WE HAVE PARITY AROUND THE WORLD WITH RESPECT TO INSPECTIONS. |
| 00:19:01 | TAKING $319 MILLION AWAY FROM THE FDA WOULD BE CATASTROPHIC. |
| 00:19:06 | WE JUST CAN'T ALLOW THAT TO HAPPEN. |
| 00:19:10 | THIS IS THE BEST OPPORTUNITY. |
| 00:19:14 | IT'S NOT THE ONLY ONE. |
| 00:19:16 | JOHN AND I ARE GOING TO WORK TOGETHER ON PATENT SETTLEMENTS. |
| 00:19:23 | WE'RE GOING TO SHOW HOUSE THEY HAVE SAVED TENS OF BILLIONS OF DOLLARS. |
| 00:19:29 | AFFORDABLE MEDICINE AND THE BRANDS AND THE GENERICS WORKING TOGETHER IN A COOPERATIVE WAY, IS ESSENTIAL TO OUR INDUSTRY. |
| 00:19:44 | FIRST LUNCH JOHN AND I SAID CHANGE IS HAPPENING AT A DIZZYING PACE. |
| 00:19:50 | BUT THE MOR THAT JOHN AND I GET TO TALK TOGETHER THE MORE THAT ALL OF YOU IN THIS ROOM COLLABORATION IS THE WAY TO GO. |
| 00:20:05 | SOMETIMES YOU HAVE TO CONTEST ONE ANOTHER AND FIGHT IT OUT IN A FAIR WAY. |
| 00:20:11 | YOU ARE OBVIOUSLY REPRESENTING CON STIT WNTCY. |
| 00:20:15 | WE HAVE GOT COLLABORATE. |
| 00:20:17 | IT REALLY IS, THE NATION DEFENDS ON US TO DO IT RIGHT. |
| 00:20:22 | AND I THINK THE MODEL HAS BEEN DEMOCRAT TRAITED IN THIS ROOM. |
| 00:20:27 | THE PRIVATE SECTOR LEADERSHIP HAS BEEN DEMANDED. |
| 00:20:33 | I BELIEVE IT'S A MODEL FOR THE FUTURE. |
| 00:20:38 | >> WELL SAID, LET ME ADD A COUPLE OF OTHER THINGS. |
| 00:20:44 | THERE ARE OTHER LEVELS OF ACTIVITY THAT ARE UNDERWAY. |
| 00:20:52 | ONE OF THE THINGS THAT THE PARTNERSHIP FOR SAFE MEDICINE HAS BEEN DOING IS RECOGNIZING THIS IS A GLOBAL ISSUE. |
| 00:21:01 | THEY ARE VERY IMPORTANT PROGRAMS IF WE'RE GOING TO BE SUCCESSFUL GLOBALLY. |
| 00:21:16 | THE OTHER THING I MENTIONED AND YOU TALKED ABOUT IT EARLIER THIS MORNING. |
| 00:21:20 | THE NATIONAL ASSOCIATION OF STATE PHARMACY BOARDS AND THE WORK THAT THEY DO IS VERY, VERY CRITICAL. |
| 00:21:28 | I THINK THE COMMISSIONER THIS MORNING POINTED OUT THAT THERE WERE JUST A DOZEN CERTIFY EDIED THEY ARE SELLING BOGUS MEDICINES. |
| 00:21:52 | THAT WORKS WITH THE SECURITY DIRECTORS OF 25 GLOBAL MANUFACTURERS AND THEY HAVE A COUNTERFEIT INCIDENT SYSTEM. |
| 00:22:08 | THE COALITION FOR PATIENT SAFETY AND MEDICINE INTELTY IS THERE YOU TALKED ABOUT THAT. |
| 00:22:17 | THAT'S A DRIVING FORCE BEHIND THE SAFE DOSES. |
| 00:22:26 | SOME 27 ORGANIZATION. |
| 00:22:28 | BOTH GENERIC AND BRANDED REPRESENTS THE BROAD HEALTH CARE SYSTEM THAT IS PUTTING TOGETHER AND BEEN MENTIONED SEVERAL TIMES HERE THEY ARE PUTTING TOGETHER THE SPECK FOR WHAT ELECTRONIC SYSTEMS ARE GOING TO BE NECESSARY AND OTHER MANAGEMENT SYSTEMS SO THAT WE CAN ADDRESS THIS PROBLEM. |
| 00:22:51 | THE CENTER FOR SAFE INTERNET PHARMACY S PHARMACIES DEDICATED TO SERVING PATIENTS. |
| 00:23:05 | YOU ARE HERE RIGHT? |
| 00:23:08 | THERE YOU ARE. |
| 00:23:12 | ONE OF THE THINGS THAT WAS THE MOST DISTURBING WHEN SHE AND HER TEAM WERE TEACHING US ABOUT WHAT THEY HAVE LEARNED ABOUT THE THREE CONCERNS ARE I THINK I GOT THEM RIGHT. |
| 00:23:40 | AND THEY ARE CONCERNED THAT SOMEBODY IS GOING TO TALE THEIR FINANCIAL DATA. |
| 00:23:46 | THEY FIRST OUGHT TO BE CONCERNED THAT THEY WILL DIE. |
| 00:23:49 | THAT TELLS US THERE IS A LOT OF EDUCATION THAT HAS TO BE DONE. |
| 00:23:55 | WHETHER YOU EYRE DEALING WITH AVAILABILITY OF COUNTERFEIT MEDICINE S MEDICINES OR YOU ARE DEALING WITH PRESCRIPTION MEDICINE ABUSE OR HOW WE HAVE MANAGED MEDICINES IN A BROAD ENVIRONMENT, MOST OF IT ALWAYS COMES BACK TO EDUCATION. |
| 00:24:36 | ULTIMATELY THE BEST DEFENSE IS GOING TO BE AN EDUCATED PATIENT. |
| 00:24:45 | >> I KNOW, JOHN, YOU HAD MENTIONED PHARMACEUTICAL SECURITY INSTITUTE AND TOM IS HERE. |
| 00:24:51 | THAT DATA AND THE TREND OF THE DATA, SOME OF WHICH IS SEEING A BIT OF A DECREASE THIS YEAR. |
| 00:24:56 | AND TO SOME PEOPLE THEY FEEL THAT'S A BETTER SCENARIO AND BETTER SITUATION AND MAYBE BETTER OUTCOME IN TERMS OF WHAT WE'RE ALL TRYING TO ACHIEVE. |
| 00:25:05 | DO YOU FEEL AS THOUGH THAT IS ATTRIBUTED TO BETTER ENFORCEMENT, BETTER UNDERSTANDING? |
| 00:25:12 | BETTER EDUCATION? |
| 00:25:27 | >> THEY HAVE HAD AN IMPACT. |
| 00:25:30 | BUT, I THINK THERE IS NO REASON TO BE COMPLACENT. |
| 00:25:35 | WE THINK THIS IS A TREND. |
| 00:25:36 | I AM ASTOUNDED AT THE CREATIVITY AND IMAGINATION OF THE THE STATISTICS LOOK BETTER THIS YEAR THAN THE LAST COUPLE OF YEARS. |
| 00:26:07 | BUT I DON'T THINK THAT SAYS LET UP AT ALL. |
| 00:26:15 | IT COULD MEAN THAT THEY ARE WORKING. |
| 00:26:19 | AND CONGRATULATIONS, TOM. |
| 00:26:21 | I CAN ONLY SEE HIS LIGHTS. |
| 00:26:22 | >> BEHIND THE PODIUM. |
| 00:26:25 | >> RALPH? |
| 00:26:26 | >> I WOULD JUST REINFORCE WHAT JOHN JUST SAID. |
| 00:26:32 | I DO COMMEND THE WORK OF THE PEOPLE IN THE ROOM WHO HAVE DONE A WONDERFUL JOB. |
| 00:26:44 | WE HAVE GOT TO STEP ON IT EVEN HARDER TO GET THIS IDENTIFICATION OUT AND TO MAKE SURE WE ARE PROTECTING THE QUALITY OF LIVES, EVEN LIVES THEMSELVES. |
| 00:26:55 | I DO WANT TO EMPHASIZE ONE THING. |
| 00:27:04 | I HOPE THAT THE VISUAL THAT YOU TAKE AWAY FROM THIS PART OF THE DAY ANYWAY IS THE THREE OF US UP HERE STANDING UNITED ON THESE ISSUES. |
| 00:27:20 | I BELIEVE THAT'S WHAT WE WANT TO CONVEY. |
| 00:27:23 | ON THESE ISSUES, WE STAND UNITED. |
| 00:27:29 | YOU TALKED ABOUT AND I TALKED ABOUT THE WONDERFUL ALLIANCE AND SECURITY ALLIANCE AND WHAT WE'RE TRYING TO DO ON THE HILL IT'S POSSIBLE. |
| 00:27:49 | YOU AND I THINK VERY STRONGLY ALONG THESE LINES THAT FOR SOME IN THOSE DAYS OF JUNE, THE PERFECT BECAME THE ENEMY OF THE GOOD. |
| 00:28:02 | IT TOOK AN ENORMOUS EFFORT TO GET IT ALL TOGETHER. |
| 00:28:05 | I WAS GOING THROUGH THE CLIPS OF SPRINGTIME. |
| 00:28:18 | AND WE GOT THIS CLOSE. |
| 00:28:19 | I THINK AT THE VERY END, PERFECT WAS THE ENEMY OF THE GOOD. |
| 00:28:24 | WE HAVE GOT TO BE BIPARTISAN AND REALISTIC. |
| 00:28:28 | WE HAVE GOT TO BE PRAGMATIC. |
| 00:28:30 | I THINK THAT APPLIES TO EVERYTHING THAT WE WORK ON. |
| 00:28:37 | THAT ENHANCEMENT CODE IS ESSENTIAL AND HOPEFULLY WE CAN GET THINK IT YEAR BUT IF WE DON'T WE HAVE TO GET IT NEXT YEAR. |
| 00:28:45 | >> I JUST HAVE TO ASK, HAVE YOU EVER FELT AS THOUGH YOU HAVE MEMBERS OF CONGRESS STARTLED BY THE STRENGTH OF THE RELATIONSHIP OR THE FACT THAT YOU DO AGREE ON SO MUCH? |
| 00:29:04 | >> BEFORE WE EVER GOT TOGETHER, THERE WERE CERTAINLY MANY OPPORTUNITIES. |
| 00:29:13 | I DO THINK WE STARTED OFF ON THE RIGHT FOOT AND JOHN AND I HAD AN OPPORTUNITY TO WORK TOGETHER WHEN I WAS THE PRESIDENT ON HEALTH CARE AND JOHN WAS WITH US ON THE BUSINESS ROUND TABLE. |
| 00:29:25 | WE MADE SURE THOUGH, FROM THAT FIRST LAUNCH TO ACKNOWLEDGE WHERE THE DIFFERENCES WERE GOING TO BE AND WE'RE FIERCE COMPETITORS. |
| 00:30:00 | >> AND I SAID IT WAS AN IMPORTANT PART OF THE PROCESS BY WHICH MEDICINES BECOME MORE AFFORDABLE. |
| 00:30:07 | AND WE LOVE THEM ALL. |
| 00:30:08 | THEY ARE OUR CHILDREN. |
| 00:30:10 | >> AND THEIR CHILDREN HAVE DONE SUCH A GREAT JOB. |
| 00:30:13 | IT IS AN AMERICAN SUCCESS STORY. |
| 00:30:17 | 80%. |
| 00:30:18 | 3.2 BILLION OUT OF 4 BILLION PRESCRIPTION DRUG SS SAVING A TRILLION DOLLARS OVER FOUR YEARS. |
| 00:30:31 | >> THANKS FOR SUPPORTING THE NEXT GENERATION. |
| 00:30:36 | >> WE CAN'T SUCCEED UNLTS YOU DO. |
| 00:30:41 | >> THIS IS ACTUALLY BECOMING AWKWARD. |
| 00:30:44 | I DO WANT TO SAY, TOO, IT HAS ACTUALLY BEEN ALMOST A CAST OF ISSUES THAT HAVE BEEN DISCUSSED EVEN THROUGH THE COURSE OF TODAY. |
| 00:30:53 | THERE WAS A DISCUSSION ABOUT A NUMBER OF UNIFIED AREAS. |
| 00:30:57 | THERE WAS ME OCCASION THAT SALLY TALKED ABOUT AND I THINK HOLDS ON THE FDA AND THE REGULATORY STRUCTURE THAT WE HAVE. |
| 00:31:13 | IN SOME CASES I THINK IT IS GETTING TO THE TOO CHUMMY PART AND WE SHOULD PROBABLY TAKE QUESTIONS FROM THE AUDIENCE. |
| 00:31:20 | WE'RE GOING TO OPEN IT UP FOR QUESTIONS. |
| 00:31:23 | PLEASE RAISE YOUR HAND AND IDENTIFY YOURSELF, YOUR ORGANIZATION AND IF IT'S A BROAD QUESTION OR DIRECTED AT A PANELIST THEMSELVES. |
| 00:31:33 | WE COULD START HERE UP FRONT. |
| 00:31:45 | >> GOOD AFTERNOON. |
| 00:31:46 | MY NAME IS KEVIN AND I'M WITH THE STATE OF TELL WARE DIVISION OF PUBLIC HEALTH. |
| 00:31:51 | YOU ALL ARE TALKING ABOUT COLLABORATIONS WITH THE FDA, HAVE YOU DISCUSSED PARTNERING WITH THE STATES AS WELL. |
| 00:32:06 | >> ABSOLUTELY. |
| 00:32:07 | MY LAUNDRY LIST, I SHOULD HAVE AND HOW FORTUITOUS, THE STATE OF DELAWARE. |
| 00:32:14 | SINCE YOUR GOVERNOR IS THE CHAIRMAN OF THE NATIONAL GOVERNORS ASSOCIATION. |
| 00:32:20 | WE ARE WORKING WITH THE GOVERNOR'S ASSOCIATION ON THE VARIETY OF ISSUES. |
| 00:32:27 | SO, YES, WITH BOTH THE GOVERNORS AND ATTORNEYS GENERAL. |
| 00:32:35 | >> I CERTAINLY AGREE WITH THAT. |
| 00:32:38 | WE JUST HAPPEN TO BE WITH THE STATE ATTORNEYS GENERAL LAST NIGHT. |
| 00:32:43 | AND HAD AN OPPORTUNITY ALSO TO MEET GOVERNOR CHRISTY JUST A FEW WEEKS AGO IN TAMPA. |
| 00:32:51 | WE HAVE TO WORK HAND IN HAND WITH STATE LAW ENFORCEMENT AGENCY S AGENCIES WE HAVE GOT A STATE BRANCH. |
| 00:33:11 | AS WE TALK ABOUT NATIONAL AND INTERNATIONAL, THE STATE AND LOCAL LEVEL IS JUST AS IMPORTANT. |
| 00:33:34 | >> I WAS CURIOUS AS TO YOUR THOUGHTS ON THE PLAUSIBILITY OF THE NEW DO MAIN DOT PHARMACY AND WHAT YOU THINK THAT IMPACT MIGHT BE. |
| 00:33:50 | >> NO, IT -- THAT'S PROBABLY A QUESTION THAT IS BETTER FOR THE PHARMACIST. |
| 00:33:56 | I THINK, YOU KNOW, THE GENERAL REACTION IS IF I UNDERSTAND YOUR QUESTION CORRECTLY, IT SHOUMTD BE HELPFUL. |
| 00:34:23 | PEOPLE ARE SO DAM CLEVER. |
| 00:34:27 | AND, WHETHER IT'S FINANCIAL SERVICES OR COUNTERFEIT MEDICINES OR ANYWAY THAT THEY ARE TRYING TO GET INTERCERTAINAL DATA OR I THINK IT WILL TAKE A LOT MORE THAN THAT. |
| 00:34:53 | I WILL LOOK INTO IT. |
| 00:34:55 | I AM REALLY NOT THAT FAMILIAR WITH IT. |
| 00:34:57 | BUT WE WORK WITH SO MANY OF THE OF THE PHARMACISTS' ORGANIZATIONS. |
| 00:35:02 | I'LL FIND OUT MORE ABOUT IT. |
| 00:35:04 | >> QUESTION? |
| 00:35:05 | RIGHT BEHIND YOU. |
| 00:35:08 | >> THANK YOU SO MUCH. |
| 00:35:09 | SO, I COMPLETELY AGREE THAT THE NEWS STORY TODAY IS THAT YOU'RE SITTING UP HERE TOGETHER AND KIND OF HOLDING HANDS ON THIS ISSUE. |
| 00:35:17 | I WANT TO COMMEND YOU. |
| 00:35:19 | I HOPE THAT YOUR COUNTER PARTS IN OTHER PARTS OF THE WORLD COULD LEARN FROM THIS, TOO, AND MAYBE IT'S SOMETHING THAT YOU COULD REACH OUT WITH COUNTERPARTS AND SAY THIS IS SOMETHING WHERE WE NEED TO BE STANDING TOGETHER BECAUSE IN OTHER PARTS OF THE WORLD, THIS IS EVEN MORE COMPLICATED FOR THE TWO INDUSTRIES, INNOVATIVE AND GENERICS, BUT THIS IS SOMETHING WE HAVE TO WORK ON. |
| 00:35:46 | YOU SENT AN IMPORTANT MESSAGE THAT SHOULD CARRY OVER TO THE GLOBAL VIEW. |
| 00:35:52 | >> AND THAT'S A VERY GOOD POINT BECAUSE AS YOU KNOW, WHETHER IT'S IFPMA, WHICH HAS VARIOUS STRONG GLOBAL JURISDICTION OR IS THE INDIVIDUAL COUNTRY ASSOCIATIONS, IT IS THE COMPANIES ARE DRIVING US ALL TO WORK COLLABORATIVELY BECAUSE THE ISSUE REQUIRES THAT COLLABORATIVE WORK. |
| 00:36:20 | AS I MENTIONED, THE GROUP DECIDED TO TAKE ON THIS PROJECT WITH INTERPOL, AND THAT'S GOT STRONG SUPPORT FROM THE JAPANESE MANUFACTURERS, THE EUROPEAN MANUFACTURERS, THE UK MANUFACTURERS AND THE U. |
| 00:36:38 | S. MANUFACTURERS. |
| 00:36:39 | >> NHS BEFORE JOHN AND I STARTED HAVING LUNCH TOGETHER, JOHN MENTIONED THE MEETING IN JANUARY WHERE WE GET TOGETHER WITH OUR COUNTERPARTS THROUGHOUT THE PHARMACEUTICAL INDUSTRY, MANY OF THE PHARMACISTS ORGANIZATIONS AND WHOLESALERS AND DISTRIBUTORS AND TRY TO COME UP WITH AN ITEM, A TOP PRIORITY RELATING TO THE ISSUES THAT WE CAN ALL UNITE AROUND. |
| 00:37:07 | IN DECEMBER, I'M GOING TO JAPAN FOR THE INTERNATIONAL GENERIC ASSOCIATION, AND THIS IS DEFINITELY SOMETHING I WOULD LIKE TO PUT ON THE AGENDA FOR THE GENERIC ASSOCIATIONS AROUND THE WORLD. |
| 00:37:16 | AND I WOULD HOPE WE COULD WORK JOINTLY, WORKING WITH GOVERNMENTS AND NGOs AROUND THE WORLD. |
| 00:37:26 | AND SEE WHETHER WE CAN INSTILL THE SAME KIND OF SPIRIT OF COLLABORATION AND TRYING TO GET THINGS DONE. |
| 00:37:33 | >> ANOTHER QUESTION, YES. |
| 00:37:34 | ONE OVER HERE. |
| 00:37:41 | >> HI, I'M REBECCA ADAMS. |
| 00:37:44 | I WONDERED IF YOU COULD TALK A LITTLE MORE ABOUT PROSPECT FOR CONGRESSIONAL ACTIVITY IN A LAME DUCK SESSION AND IN TERMS OF TRACK AND TRACE, COULD YOU TELL US WHAT VEHICLE MIGHT BE USED AND MORE SPECIFICS ABOUT WHAT YOU EXPECT? |
| 00:37:58 | >> A LONG DISCUSSION OR A SHORT DISCUSSION? |
| 00:38:03 | >> SCOTT SAID IT COULD BE LONG OR VERY SHORT. |
| 00:38:07 | A CONVENTIONAL WISDOM RIGHT NOW ABOUT THE LAME DUCK IS THAT IT'S GOING TO BE VERY LAME. |
| 00:38:14 | THERE'S NOT GOING TO BE A LOT HAPPENINGERING ACCORDING TO MOST INDIVIDUALS. |
| 00:38:19 | AND I HAVE TALKED TO SOME OF THE RANKING REPUBLICANS AND DEMOCRATS, AND THEY HAVE SAID THE ONLY SENATORS AND REPRESENTATIVES TALKING ABOUT REALLY DOING SOMETHING IN A MAJOR WAY ARE THOSE THAT ARE RETIRING OR WHO HAVE BEEN DEFEATED AND ARE MOVING ON AND WANT TO LEAVE A LEGACY. |
| 00:38:35 | THAT MAY NOT BE FAIR. |
| 00:38:36 | THAT MIGHT BE AN OVERSTATEMENT. |
| 00:38:39 | IT'S HARD TO SEE IN THAT FIVE OR SIX WEEKS, GIVEN WHAT WE HAVE EXPERIENCED IN RECENT YEARS, HOW DIVISIVE THINGS ARE NOW, HOW COMPLICATED THESE ISSUES ARE, THEY HAVE TO BE ADDRESSED. |
| 00:38:54 | SOME PEOPLE ARE TALKING ABOUT A DOWN PAYMENT, I THINK, SENATOR DIRKEN SAID A $55 BILLION DOWN PAYMENT, AND A FRAMEWORK FOR THE APPROPRIATE COMMITTEES TO DO X, Y, AND Z OVER SIX MONTHS IN 2013. |
| 00:39:11 | I'M NOT SURE THEY CAN GET EVEN THAT BECAUSE IT'S HARD TO TELL THE COMMITTEES OF JURISDICTION HERE'S WHAT YOU'RE GOING TO DO OVER THE NEXT SIX MONTHS. |
| 00:39:21 | I'M NOT OPTIMISTIC ABOUT THE BIG PICTURE IN GETTING SOMETHING DONE BEFORE CHRISTMAS EVE OR NEW YEAR'S EVE. |
| 00:39:32 | I'M CAUTIOUSLY OPTIMISTIC ABOUT THE FIRST HALF OR SO OF 2013. |
| 00:39:37 | I DON'T THINK THERE'S ANY CHOICE. |
| 00:39:38 | I THINK DEMOCRATS AND REPUBLICANS ARE GOING TO HAVE TO FIGURE IT OUT. |
| 00:39:44 | WITH RESPECT TO SAN ANTONIO SPURS SENATORS BUHR AND BENNETT, I CAN'T STATE ENOUGH HOW OVERCOMMITTED THEY ARE TO FINDING A VEHICLE. |
| 00:39:54 | YOU KNOW YOU HAVE TALKED TO THEM, TOO. |
| 00:39:57 | THE FIRST AVAILABLE VEHICLE, WE'RE GOING AFTER IT. |
| 00:39:59 | WHETHER IT'S GOING TO BE AVAILABLE IN THE LATTER HALF OF NOVEMBER, DECEMBER, I DON'T KNOW. |
| 00:40:04 | BUT I KNOW THERE WILL BE ONE AVAILABLE PRETTY EARLY ON IN 2013. |
| 00:40:09 | THEY'RE NOT GOING TO LET GO OF THIS. |
| 00:40:11 | WE'RE NOT GOING TO LET GO OF THIS. |
| 00:40:12 | I THINK OUR COALITION ONLY GETS BETTER. |
| 00:40:15 | AND HOPEFULLY SOME OF THE RECALCITRANT PARTICIPANTS IN THE NEGOTIATIONS IN JUNE WILL ALSO TAKE THE ADMISSION I SHARED WITH EVERYBODY, LET'S NOT LET THE PERFECT BE THE ENEMY OF THE GOOD AND LET'S PASS SOMETHING THAT WILL DO SO MUCH GOOD WITH RESPECT TO PROTECTING THE SUPPLY CHAIN ALL AROUND THE COUNTRY AND ALL AROUND THE WORLD. |
| 00:40:42 | >> RALPH AS USUAL IS RIGHT ON THIS. |
| 00:40:44 | JUST A COUPLE OF OTHER PERSPECTIVES TO ADD TO IT. |
| 00:40:49 | OUR JOB AT THE COALITION IS TO WORK TO BE READY TO RESOLVE DIFFERENCES, SO WHENEVER THE VEHICLE COMES ALONG, WHEN IT COMES ALONG, IT CAN BE USED. |
| 00:41:01 | THE OTHER THING I WOULD POINT OUT IS THAT WHEN WE'RE UNABLE TO REACH AGREEMENT IN JUNE BECAUSE OF OTHER CIRCUMSTANCES AND CONCERN ABOUT DEADLINES, BOTH THE SPEAKER OF THE HOUSE AND THE MAJORITY LEADER OF THE SENATE SAID WE WILL FIND A VEHICLE. |
| 00:41:22 | AS SOON AS IT APPEARS. |
| 00:41:23 | SO YOU HAVE BIPARTISAN SUPPORT FOR GETTING THIS DONE. |
| 00:41:29 | AND SO THE COALITION AND EACH OF OUR INDIVIDUAL ORGANIZATIONS ACTIVITIES HAVE BEEN WHEN YOU HAVE THAT KIND OF OVERSIGHT AND THOSE KINDS OF GODFATHERS, WE NEED TO GET OUR WORK DONE. |
| 00:41:49 | THEY'LL FIND THAT PART. |
| 00:41:50 | >> AN OPPORTUNITY FOR ONE MORE QUESTION. |
| 00:42:07 | >> HI, I'M WONDERING IF YOUR ORGANIZATIONS ARE TALKING A POSITION POSITION. |
| 00:42:19 | CAN WE CONSIDER THE PATIENT AND AN OPPORTUNITY TO VERIFY MY MEDICINE IS BASED. |
| 00:42:25 | I KNOW IT WILL DISRUPT HOW THINGS ARE SHIPPED NOW, PARTICULARLY THE BIG PBMs BECAUSE EVERYTHING COMES IN BIG BOTTLES AND GETS PARCELLED DOWN AT THE PHARMACY LEVEL, BUT WE WERE TALKING ATBOUT THIS EARLIER. |
| 00:42:39 | IT SEEMS LIKE IF THEY CAN DO STUFF LIKE THAT IN AFRICA, WE CAN DO IT HERE. |
| 00:42:44 | >> DID YOU SAY THE 2-D BAR CODE? |
| 00:42:46 | >> NO, THE NUMBER ON THE BOTTOM OF THE BOX THAT YOU SCRATCH OFF AND THEN YOU CALL A NUMBER ON YOUR CELL PHONE OR I'M SORRY, TEXT, AND THEN IT VERIFIES THAT YES, THIS IS A LEGITIMATE MEDICINE. |
| 00:42:59 | >> IF WE COULD ADD TO THAT, THERE'S A GENERAL CONVERSATION ABOUT TECHNOLOGY. |
| 00:43:04 | THAT'S PART OF THE CONVERSATION YOU WERE TALKING ABOUT WITH WHAT IS BEING DONE BY THE COALITION OR DISCUSSED. |
| 00:43:10 | >> THERE ARE A NUMBER OF PROMISING TECHNOLOGIES. |
| 00:43:14 | THE KEYS AS HAVE BEEN DISCUSSED BEFORE, IT HAS TO BE AVAILABLE, USEFUL, AFFORDABLE, AND EVERYONE IN THE CHAIN HAS TO BE ABLE TO USE IT. |
| 00:43:23 | I HAVE SEEN TECHNOLOGIES AND ANOTHER COALITION HAS SEEN TECHNOLOGIES THAT CAN BE USED AT THE DIFFERENT LEVELS AND A QUESTION OF WHICH ONES CAN BE INCORPORATED AND HOW THEY'RE BEING INCORPORATED. |
| 00:43:38 | NONE SPECIFIC. |
| 00:43:39 | THERE ARE TECHNOLOGIES THAT ARE OUT THERE THAT DOESN'T MAKE ANY DIFFERENCE WHO DID IT. |
| 00:43:44 | IT CAN BE READ IN CERTAIN WAYS IF IT'S DONE A CERTAIN WAY. |
| 00:43:48 | SO IT'S KIND OF, YOU KNOW, STANDARDIZED THE PERFORMANCE, NOT THE PRODUCT IN AND OF ITSELF. |
| 00:43:56 | THAT'S PART OF THE DISCUSSION GOING ON. |
| 00:43:59 | BUT I THINK WE'RE CONVINCED THAT ALL OF US IN THE COALITION, THOSE TECHNOLOGIES EXIST. |
| 00:44:06 | THEY CAN BE APPLIED. |
| 00:44:08 | WE JUST NEED THE RIGHT FRAMEWORK TO BE ABLE TO DO THAT. |
| 00:44:13 | >> RALPH? |
| 00:44:14 | >> AND THAT CERTAINLY, AS YOU KNOW, IS THE THRUST OF THE RX TECH BILL, THE TECHNOLOGICAL ENHANCEMENT ACT AND SERIALIZING THE END POINT AUTHENTICATION. |
| 00:44:28 | I THINK IT'S A QUESTION OF EXACTLY HOW WE'RE GOING TO DO IT, BUT IT SEEMS TO BE A CONSENSUS THAT IT HAS TO BE ENHANCED TECHNOLOGY. |
| 00:44:36 | IT'S GOT TO BE SIMPLE. |
| 00:44:37 | IT'S GOT TO BE ACCESSIBLE. |
| 00:44:42 | IT'S GOT TO WORK, GOT TO BE EFFECTIVE. |
| 00:44:45 | I THINK SOMETHING LIKE THIS IS GOING TO HAPPEN, I BELIEVE IT'S GOING TO HAPPEN PRETTY SOON. |
| 00:44:49 | >> I JUST WANT TO PIGGY BACK ON A COMMENT MADE EARLIER. |
| 00:44:53 | THIS HAS BEEN A GREAT CONVERSATION AND CERTAINLY THE PICTURE IS GOING TO SPEAK 1,000 WORDS, BUT I WANT TO THANK JOHN AND RALPH. |
| 00:45:02 | PLEASE JOIN ME IN A ROUND OF APPLAUSE. |
| 00:45:06 | [ APPLAUSE ] >> THANK YOU. |
| >>> |
Loading...